Skip to content

A Single-Center, Prospective, Open Labeled, Phase IV Clinical Study to Evaluate Safety and Efficacy of MY V3 Immune Herbal Capsules in Healthy Participants.

A Single-Center, Prospective, Open Labeled, Phase IV Clinical Study to Evaluate Safety and Efficacy of MY V3 Immune Capsules in Healthy Participants. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067457
Enrollment
32
Registered
2024-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Sidhva Herbal and Foods Pondicherry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Male/females of greater than or equal to 18 years of age at the time of consent 2) Patient / Legally Acceptable Representative who can and willing to provide Informed Consent 3) Confirmed anemia 4) Clinically stable for at least 1 month prior to entry into the study 5) Score on the Insomnia Severity Index (ISI) measure greater than or equal to 15

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women or women of childbearing potential who did not use oral contraceptives or an intrauterine device 2) Administration of another investigational drug within 1 month before screening or planned during the study period 3) Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol 4) Diagnosis of other primary sleep disorders 5) Psychotherapy within the past six months 6) Shift workers 7) Current or expected use of hypnotic medications 8) Renal or hepatic disease 9) History of Neurological disorder or cardiovascular disease raising safety concerns 10) Excessive coffee or cigarette use 11) Recent surgery 12) Current alcohol/substance use disorder 13) Current major depressive episode

Design outcomes

Primary

MeasureTime frame
1.Improvement in the Immune Status Questionnaire (ISQ) from baseline to end of the study 2.Improvement in Hemoglobin level from baseline to end of the studyTimepoint: 2 months

Secondary

MeasureTime frame
1.Improvement in the Liver function test (LFT) Parameters. 2.Improvement in the (Pittsburgh Sleep Quality Index PSQI) from base line to end of the study. 3.Number of Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)Timepoint: 2 months

Countries

India

Contacts

Public ContactDr MS Ramasamy

Sanjeev Biomedical Research Center

ramasamy.mani@gmail.com9176049309

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026